Marijuana retailer Cresco Labs has agreed to buy Origin House for $825 million in one of the largest-ever US pot deals

Hollis Johnson/Business Insider

• Cresco Labs has agreed to buy Origin House in an approximately $825 million deal.
• The deal would be the largest public acquisition in the US cannabis industry to date, according to the company.
• Nearly $1 billion deals are becoming commonplace in the US cannabis industry as companies chase down what’s set to be a $75 billion market. 

The marijuana retail chain Cresco Labs has agreed to buy marijuana retailer Origin House in an approximately $825 million deal.

The deal would be the largest public acquisition in the US cannabis industry to date, according to the company. The transaction is expected to close in June.

"Following the closing of this acquisition, Cresco brands will be in over 725 dispensaries across the country, giving us the largest and most strategic distribution footprint of any cannabis company in the United States," Cresco Lab’s CEO Charlie Bachtell said in a statement. 

Based on the terms of the deal, Origin House shareholders will each receive 0.8428 subordinate voting shares of Cresco Labs. 

Read more: A hot marijuana startup fresh off a $75 million raise just scooped up an exec from ModCloth to lead its retail push, and it’s part of a growing trend

Cresco went public on the Canadian Securities Exchange (CSE) in December of last year. The deal marks the Chicago-based company’s push into the California market, where Origin House, formerly CannaRoyalty Corp, has a presence in more than 500 dispensaries.

Nearly $1 billion buyouts have become commonplace in the US cannabis industry, as companies compete for scale in an industry that some Wall Street analysts say could be a $75 billion market as more states open their doors to commercialized pot.

In March, Harvest Health & Recreation announced its intent to acquire Chicago-based Verano Holdings in an approximately $850 million all-stock transaction.

IAnthus, a New York-based marijuana company, acquired MPX Bioceutical in a $640 million deal in October of last year. And MedMen, a California cannabis chain, acquired PharmaCann in a $682 million all-stock transaction in October as well.

Sign up here for our weekly newsletter Wall Street Insider, a behind-the-scenes look at the stories dominating banking, business, and big deals.

• Read more:
• A top venture investor that’s backed companies like Bird and TheRealReal explains why CBD is primed to explode
• Biotech, CBD drinks, and a hot vape company: Here’s where all the top marijuana VCs are looking to write checks this year
• Meet the big-shot lawyers who are turning weed into a $194 billion industry
• Check out our exclusive list of the top 12 venture capital firms making deals in the booming marijuana industry

NOW WATCH: Elon Musk sent a $100K Tesla Roadster to space a year ago. It has now traveled farther than any other car in history.

See Also:

• Lawmakers just took a huge step toward passing a critical bill that could pave the way for banks to work with marijuana companies
• Health-insurance startup Clover Health just laid off 25% of its staff months after raising $500 million
• Wall Street is losing its battle against encrypted apps like WhatsApp and WeChat as it tries to police employee communications — and even regulators are stumped

Source: Business Insider – jberke@businessinsider.com (Jeremy Berke)